Cofoe Medical Technology Co., Ltd. disclosed on 24 July 2026 that it repurchased a total of 1,094,900 A shares on the Shenzhen Stock Exchange between 22 and 24 July 2026. The aggregate cash outlay reached RMB 57.93 million, with volume-weighted average prices ranging from RMB 52.61 to RMB 54.19 per share. The repurchased shares represent 0.54 % of the company’s 201.70 million issued shares (excluding treasury shares) before the transactions. All shares are earmarked for cancellation; none will be held as treasury stock.

On 24 July 2026 alone, the company bought back 190,000 shares at prices between RMB 53.75 and RMB 54.68, spending RMB 10.30 million.

Following the latest transactions, Cofoe Medical’s issued share capital remains at 208.90 million shares, comprising 201.70 million outstanding shares and 7.20 million shares held in treasury. This structure will only reflect a reduction once the newly repurchased shares are formally cancelled.

The board confirmed that the buybacks were properly authorised and conducted in compliance with the Hong Kong Listing Rules and the Shenzhen Stock Exchange’s repurchase regulations.